Everything below concerns prothymosin alpha. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-02-14. Numbers and descriptions here follow the published literature rather than marketing material.
胸腺素α1（thymosin alpha 1，Tα1）是一种由28个氨基酸组成的酸性肽，N端被乙酰化，分子量约为3108道尔顿。该肽最早从牛胸腺组织提取物中分离，属于胸腺素组分5的一个成分。其序列在不同哺乳动物中高度保守，提示其具有基本的生物学功能。名称中的“α1”指其在电泳中的迁移位置，并非表示亚型编号。它既存在于胸腺，也存在于脾脏和淋巴结等免疫组织。
20世纪70年代，研究者从胸腺提取物中纯化出多种小肽，Tα1是其中被较早表征的一种。最初的制备依赖组织匀浆和层析步骤，产量低且成分复杂。随着固相肽合成技术成熟，实验室和工业界能够生产与天然序列一致的合成版本。合成肽的纯度可达95%以上，并可通过反相高效液相色谱和质谱进行鉴定。这一转变使研究不再依赖动物胸腺来源。
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
| Property | Value | Notes |
|---|---|---|
| 化学分类 | 线性肽 | 由28个氨基酸组成 |
| 分子量 | 约3108 Da | 合成版本一致 |
| 外观 | 白色至类白色粉末 | 冻干品 |
| 溶解度 | 易溶于水 | 微溶于有机溶剂 |
| 储存温度 | -20°C（冻干） | 溶解后2-8°C |
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated or chemically modified byproducts. Mass spectrometry confirms the expected molecular mass and can indicate acetylation state or sequence errors. Amino acid analysis and peptide mapping supply complementary sequence-level information, while endotoxin testing is relevant for preparations intended for cell or animal work. Purity figures reported by suppliers refer to the method used and are not directly comparable across laboratories unless conditions are stated.
Lyophilized material is typically treated as a hygroscopic solid that should be brought to room temperature before the container is opened, which limits condensation on the powder. Reconstitution is commonly done with sterile water or a buffered diluent, and gentle mixing is preferred over vigorous agitation to reduce foaming and surface adsorption. Because peptides can bind to plastic and glass, diluents containing a small amount of carrier protein are sometimes used in laboratory work. Working solutions are generally aliquoted and prepared fresh rather than subjected to repeated freezing and thawing.
Stability depends on temperature, pH, and the number of freeze-thaw events the sample has experienced. Freeze-dried material is commonly held at -20 °C or colder, while reconstituted liquid is kept cold and used within a short window. Extreme pH and prolonged light exposure can promote deamidation, oxidation, or aggregation, particularly at asparagine and methionine positions. Adsorption to container walls can lower the measured concentration of a dilute solution even when the peptide molecules themselves remain intact.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.
Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
== External links == Fibronectin, an Extracellular Adhesion Molecule The Fibronectin Protein Fibronectin at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Fibronectin molecular interactions Overview of all the structural information available in the PDB for UniProt: P02751 (Human Fibronectin) at the PDBe-KB. Overview of all the structural information available in the PDB for UniProt: P11276 (Mouse Fibronectin) at the PDBe-KB.
== Prognosis == With treatment, the five-year survival rate is >80%, and fewer than 30% of affected individuals require long-term dialysis. A study performed in Australia and New Zealand demonstrated that in patients requiring renal replacement therapy (including dialysis), the median survival time is 5.93 years. Without treatment, virtually every affected person will die from either advanced kidney failure or lung hemorrhages.
=== Topical/symptomatic === Topical treatment for the skin changes of scleroderma do not alter the disease course, but may improve pain and ulceration. A range of nonsteroidal anti-inflammatory drugs, such as naproxen, can be used to ease painful symptoms. The benefit from steroids such as prednisone is limited. Episodes of Raynaud's phenomenon sometimes respond to nifedipine or other calcium channel blockers; severe digital ulceration may respond to prostacyclin analogue iloprost, and the dual endothelin-receptor antagonist bosentan may be beneficial for Raynaud's phenomenon. Skin tightness may be treated systemically with methotrexate and ciclosporin. and the skin thickness can be treated with penicillamine.
However, unjustified self-medicated preventive administration of stable KI is not recommended in order to avoid disturbing the normal thyroid function. Such a treatment must be carefully dosed and requires an appropriate KI amount prescribed by a specialised physician.
Sources: en.wikipedia.org
== The economic crisis in Germany == Hitler's interest in Czechoslovakia was largely economic. Germany had the second-largest economy in the world, but German agriculture was not capable of feeding the population, and there was also a lack of many raw materials, which had to be imported. The Four-Year Plan that Hitler had launched in September 1936 to have the German economy ready for a "total war" by 1940 had seriously strained the German economy by 1937 as German government was forced to use up its foreign exchange reserves both to feed its own people and to import various raw materials to achieve the ambitious armament goals of the Four Year Plan. Though the Four Year Plan aimed at autarky, there were certain raw materials such as high-grade iron, oil, chrome, nickel, tungsten, and bauxite that Germany did not have and had to be imported. The need to import food and raw materials made Germany into Europe's second largest importer, being exceeded only by Great Britain. Moreover, hundreds of millions of Reichsmarks were spent on immense armament works such as the Reichswerke steel complex, an expensive program to develop synthetic fuel, as well as various costly chemical and metallurgical programs, all of which strained the German economy. The Great Depression was an era beset by trade wars and protectionism, which put further straining on the German export market and ability to generate foreign exchange. Moreover, the Four Year Plan with its aim of autarky led to Germany increasing its tariffs, which led other nations to do likewise in retaliation.
When sold at the anhydrous state as a desiccant with a color-indicating agent under the name Drierite, it appears blue (anhydrous) or pink (hydrated) due to impregnation with cobalt(II) chloride, which functions as a moisture indicator.
=== Confidence === The formation of the Bellido cabinet was instantly met with opposition, and in the opposition-controlled Congress, there was the risk that Congress would not give trust to the cabinet. Some believed that the Bellido cabinet was a "shock cabinet" with the attempt of baiting Congress into denying confidence twice so that it could be shut down, as it was during the 2019–2020 Peruvian constitutional crisis. A congressman from Free Peru claimed that Congress was attempting to impeach the President, and warned that if trust is denied twice then Congress will be dissolved. While Vice President Dina Boluarte rejected the possibility of dissolving Congress, it nonetheless remained a contentious issue. During the impeachment attempt against former Labor Minister Iber Maraví over his alleged link to Shining Path, then Prime Minister Guido Bellido threatened to use trust to defend Maraví. As a result, Congress passed a law which would reinterpret the question of confidence and would restrict its applicability. Justice Minister Aníbal Torres claimed that this reinterpretation would challenge the constitutional balance of power, and stated that he would challenge the reinterpretation bill via the Constitutional Court. It's worth noting that the makeup of the Constitutional Court is set to be replaced by Congress, as its current term expired in 2019 (the court remained in operation as Congress couldn't agree on successors).
== Metabolism == In the case of ET/SRTX binding to a receptor and creation of a receptor-ligand complexes in various tissues, a very slow pace of dissociation is observed. In experiments conducted on rats, half-time of SRTX-b in the ileum is about 7 min (with comparison of 2 hours in case of ET-3), while in the cerebellum, the t1/2 values are more than 2–3 hours for both SRTX-b and ET-1, and in case of ET-3, the dissociation rate is negligible. Iodinated SRTX-b binds specifically to preparations of atrial membranes with a maximum binding capacity of 110 fmol per mg of protein and a dissociation constant (KD) of 3–5 nM. SRTX-a, SRTX-b and STRX-c inhibit binding of iodinated SRTX-b in the atrium at mean inhibitory concentrations (IC50) of 30, 25 and 100 nM, respectively. Other binding experiments have also shown that 125I-SRTX-b recognizes sites in a rat cerebellum KD = 3.5 nM and cerebral cortex KD=0.3nM. Furthermore, it has been shown that:
=== Other elements === Not all elements which are found in the human body in trace quantities play a role in life. Some of these elements are thought to be simple common contaminants without function (examples: caesium, titanium), while many others are thought to be active toxins, depending on amount (cadmium, mercury, lead, radioactives). In humans, arsenic is toxic, and its levels in foods and dietary supplements are closely monitored to reduce or eliminate its intake. Some elements (silicon, boron, nickel, vanadium) are probably needed by mammals also, but in far smaller doses. Bromine is used by some (though not all) bacteria, fungi, diatoms, and seaweeds, and opportunistically in eosinophils in humans. One study has indicated bromine to be necessary to collagen IV synthesis in humans. Fluorine is used by a number of plants to manufacture toxins but in humans its only known function is as a local topical hardening agent in tooth enamel.
Sources: en.wikipedia.org
它不是经典的内分泌激素，而是一种免疫调节肽。其作用主要通过局部免疫细胞间的信号传递实现，而非经血液循环作用于远隔器官。
天然胸腺素α1主要从胸腺组织提取，也可在脾脏和淋巴结中检出。目前研究和临床使用的多为化学合成版本，不再依赖动物组织。
胸腺素组分5是牛胸腺提取物的粗组分，包含多种肽。胸腺素α1是其中一种被纯化和表征的单一肽，具有明确的28个氨基酸序列。
It corresponds to a fragment of the larger protein prothymosin alpha, which is present in many tissues. The isolated 28-amino-acid peptide was originally obtained from thymus preparations, and the pharmaceutical product is synthesized rather than extracted. The term therefore describes both a natural fragment and a manufactured drug substance.